Stock Track | MEDBOT-B Soars 5.24% Intraday on UBS Upgrade, European Certification and Policy Support

Stock Track04-16

MEDBOT-B's stock surged 5.24% during intraday trading on Thursday, reflecting strong investor sentiment toward the surgical robotics company.

The rally was driven by multiple positive developments. UBS recently upgraded its rating on the stock from "Neutral" to "Buy" and significantly raised its target price, citing robust overseas sales potential and projecting strong revenue and earnings growth over the next three years. The company also targets doubling its total revenue year-over-year, with overseas revenue expected to contribute over 80% of the total.

Additionally, the company achieved a significant milestone with its self-developed Honghu orthopedic surgical robot obtaining European CE certification, marking it as the first domestically developed joint replacement surgical robot to receive such approval. Supportive policies from Beijing and Hunan regarding surgical robot hospital adoption and reimbursement standards provided further momentum for the sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141931520?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 11:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141931520","market":"sg","top_or_hot":-1,"title":"Stock Track | MEDBOT-B Soars 5.24% Intraday on UBS Upgrade, European Certification and Policy Support","media":"Stock Track","content":"<p>MEDBOT-B's stock surged 5.24% during intraday trading on Thursday, reflecting strong investor sentiment toward the surgical robotics company.</p><p>The rally was driven by multiple positive developments. UBS recently upgraded its rating on the stock from \"Neutral\" to \"Buy\" and significantly raised its target price, citing robust overseas sales potential and projecting strong revenue and earnings growth over the next three years. The company also targets doubling its total revenue year-over-year, with overseas revenue expected to contribute over 80% of the total.</p><p>Additionally, the company achieved a significant milestone with its self-developed Honghu orthopedic surgical robot obtaining European CE certification, marking it as the first domestically developed joint replacement surgical robot to receive such approval. Supportive policies from Beijing and Hunan regarding surgical robot hospital adoption and reimbursement standards provided further momentum for the sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MEDBOT-B Soars 5.24% Intraday on UBS Upgrade, European Certification and Policy Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MEDBOT-B Soars 5.24% Intraday on UBS Upgrade, European Certification and Policy Support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-16 11:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MEDBOT-B's stock surged 5.24% during intraday trading on Thursday, reflecting strong investor sentiment toward the surgical robotics company.</p><p>The rally was driven by multiple positive developments. UBS recently upgraded its rating on the stock from \"Neutral\" to \"Buy\" and significantly raised its target price, citing robust overseas sales potential and projecting strong revenue and earnings growth over the next three years. The company also targets doubling its total revenue year-over-year, with overseas revenue expected to contribute over 80% of the total.</p><p>Additionally, the company achieved a significant milestone with its self-developed Honghu orthopedic surgical robot obtaining European CE certification, marking it as the first domestically developed joint replacement surgical robot to receive such approval. Supportive policies from Beijing and Hunan regarding surgical robot hospital adoption and reimbursement standards provided further momentum for the sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1141931520","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141931520","pubTimestamp":1776309090,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MEDBOT-B's stock surged 5.24% during intraday trading on Thursday, reflecting strong investor sentiment toward the surgical robotics company.The rally was driven by multiple positive developments....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"个股追踪|瑞银升级、欧洲认证及政策支持MEDBOT-B盘中大涨5.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"MEDBOT-B's stock surged 5.24% during intraday trading on Thursday, reflecting strong investor sentiment toward the surgical robotics company.The rally was driven by multiple positive developments. UBS recently upgraded its rating on the stock from \"Neutral\" to \"Buy\" and significantly raised its target price, citing robust overseas sales potential and projecting strong revenue and earnings growth over the next three years. The company also targets doubling its total revenue year-over-year, with overseas revenue expected to contribute over 80% of the total.Additionally, the company achieved a significant milestone with its self-developed Honghu orthopedic surgical robot obtaining European CE certification, marking it as the first domestically developed joint replacement surgical robot to receive such approval. Supportive policies from Beijing and Hunan regarding surgical robot hospital adoption and reimbursement standards provided further momentum for the sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141931520","isCrawlerRequest":true}